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Abstract Estrogen receptor beta (ERβ) has been shown to play a therapeutic role in 
inflammatory bowel disease (IBD). However, the mechanism underlying how ERβ 
exerts therapeutic effects and its relationship with P2X3 receptors (P2X3R) in rats 
with inflammation is not known. In our study, animal behavior tests, visceromotor 
reflex recording and western blotting were used to determine whether the therapeutic 
effect of ERβ in rats with inflammation was related with P2X3R. In complete Freund 
adjuvant (CFA)-induced chronic inflammation in rats, paw withdrawal threshold was 
significantly decreased which were then reversed by systemic injection of ERβ 
agonists, DPN or ERB-041. In 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced 
colitis in rats, weight loss, higher DAI scores, increased visceromotor responses and 
inflammatory responses were reversed by application of DPN or ERB-041. The 
higher expressions of P2X3R in dorsal root ganglia (DRG) of CFA-treated rats and 
those in rectocolon, and DRG of TNBS-treated rats were all decreased by injection of 
DPN or ERB-041. Mechanical hyperalgesia and increased P2X3 expression in 
ovariectomized (OVX) CFA-treated rats were reversed by estrogen replacements. 
Furthermore, the expressions of extracellular signal-regulated kinase (ERK) in DRG 
and spinal cord dorsal horn (SCDH) and c-fos in SCDH were significantly decreased 
after estrogen replacement compared with those of OVX rats. The ERK antagonist 
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U0126 significantly reversed mechanical hyperalgesia in the OVX rats. These results 
suggest that estrogen may play an important therapeutic role in inflammation through 
down-regulation of P2X3R in peripheral tissues and the nervous system, probably via 
ERβ, suggesting a novel therapeutic strategy for clinical treatment of inflammation. 
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Introduction 
Studies have shown that human pain differs between the sexes. For example, some 
chronic diseases, including migraine, temporomandibular disorders, fibromyalgia, 
arthritis and interstitial cystitis, are more prevalent in females [1-2]. Women usually 
display stronger pain perception and request more analgesics [3-4], while in 
pregnancy, increasing estrogen and progestogen have an anti-nociceptive role [5-6]. 
Experimental studies have shown that after injection of estradiol, female 
ovariectomized (OVX) rats tended to have a longer latency in hot plate and tail-flick 
experiments [7]. Mechanical hyperalgesia and allodynia in the abdomen, hind limbs 
and proximal tail of OVX rats, which result from a lack of estrogen in the body, can 
be reversed by sustaining exogenous estradiol replacement [8]. During several days or 
weeks after inflammation or injury, estrogen promotes the development of heat 
hyperalgesia and mechanical hyperalgesia [9-10]. The estrogen effects depend on the 
type, time course of pain or inflammation models, and also the level and stability of 
estrogens [7].  
It has been reported that the two classic receptors for estrogen, estrogen receptor 
α (ERα) and estrogen receptor β (ERβ) are closely related with inflammation [11-13]. 
In contrast to the long association of ERα with pain, the association of ERβ with pain 
may have a totally contradictory role to that mediated by ERα [14-16]. In nociceptive 
neurons of adult rats, 17β-estradiol inhibits transient receptor potential vanilloid 
subtype 1 (TRPV1) by activating the ERβ signal pathway [17]. In an inflammation 
model induced by complete Freund's adjuvant (CFA), the selective ERβ agonist 
ERB-131 significantly reduced the extent of inflammation and pain hypersensitivity 
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[18-19]. The specific ERβ agonist ERB-041 efficiently inhibited arthritis induced by 
Freund's adjuvant and has an anti-inflammatory effect in both arthritis and colitis [20]. 
Further, down-regulating the expression of ERβ by gene knockout exacerbated 
visceral hypersensitivity [14, 16, 21]. Although ERβ has a significant therapeutic 
effect in chronic inflammation related to pain transmission, the underlying mechanism 
is still unknown. 
 ATP and P2X3R have a long history of involvement with pain and 
inflammation [22-23]. In colitis, more internal ATP was produced and expression of 
P2X3R at the end of colorectal nerves was also increased, thus leading to 
hypersensitivity of rectocolon [24-26]. When using the antagonists of P2X3R, 
2'(3')-O-(2,4,6-trinitrophenyl) ATP (TNP-ATP) or A317491, the expression and 
function of P2X3R in DRG were inhibited, resulting in the reduction of 
hypersensitivity in chronic inflammatory pain [27-28]. Also after knock-out of P2X3R 
in a mouse model of inflammatory bowel disease (IBD), visceral motor responses 
were decreased, improving inflammatory symptoms [25]. Likewise, in acute 
inflammatory pain, activation of P2X3R at the spinal cord level and on the endings of 
primary sensory afferent nerves also promoted the development of inflammatory 
hypersensitivity 1 [27]. 
Therefore, the aim of this study is to investigate the role and the underlying 
mechanisms of ERβ activation in the treatment of chronic inflammation, including 
IBD and its relationship with P2X3R. 
 
Materials and Methods 
Animals  
Adult Sprague-Dawley female rats were used (200-250 g). As previously reported 
[29], rats were randomly divided into three groups, a group ovariectomized bilaterally 
(OVX); a group receiving the same surgical procedure without removing the ovaries 
(sham surgery), with both groups receiving vehicle injection; and a group 
ovariectomized bilaterally and receiving estrogen treatment. E2 replacement therapy 
was carried out in the ovariectomized rats 1 week after surgery by daily subcutaneous 
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injection of 17β-estradiol (30μg/kg, 0.4 mL/day); the same volume of vehicle was 
injected into sham and OVX rats daily. In these three groups, the studies of chronic 
inflammatory pain by CFA injection were carried out in the 3 weeks after estradiol 
replacement or vehicle treatment. 
In the study on a rat model of CFA-induced chronic inflammatory pain, the rats 
were randomly divided into four groups, namely a saline group, a CFA (50 µg) group, 
a DPN (3 mg/kg) group and an ERB-041 (1 mg/kg) group. In the study on a rat model 
of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model, the rats were 
randomly divided into four groups, namely a saline group, a TNBS (40 mg/kg) group, 
a DPN (3 mg/kg) group and an ERB-041 (1 mg/kg) group. All experimental 
procedures were approved by the Institutional Animal Care and Use Committee at the 
Second Military Medical University. 
 
Model of CFA -induced chronic inflammation 
As previously reported [30], CFA (100 µL) was injected into the left hind paw. The 
paw withdrawal threshold (PWT) and paw size were assessed before (baseline) and 
every 1 d after CFA injection. Before CFA was given, their basic mechanical pain 
threshold, and volume of their left paws were measured by a draining method. In brief, 
100 l CFA was applied to the planta of the left hind paw to induce inflammatory 
hyperalgesia which then developed into sustained chronic hyperalgesia, which was 
characterized by intense local redness, edema and hotness. After that, pain behavioral 
experiments were conducted on rats from the different groups every 24 hours and the 
volumes of their left hind paws were recorded; the experiments lasted for at least 8 
days. 
 
Model of TNBS-induced colitis 
All experiments were performed in the diestrus stage of the rat estrous cycle when the 
least cells were seen following vaginal smear examination. As previously reported 
[31], experimental colitis was induced by administration of an intrarectal enema (8 cm 
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from the anus) of 30% TNBS in ethanol at a dose of 40 mg/kg body weight. The 
enemas were given through a 6-Fr medical-grade polyurethane enteral feeding tube 
while the rats were under light ether anesthesia. Assessment of colitis was based on 
body weight and DAI scores (a disease activity index mainly based on weight loss, 
stool consistency and bleeding).  
 
Behavioral experiments 
Testing of PWT 
As we have reported, on the day of experimentation, rats were allowed to settle for at 
least 30 min before behavioral experiments. For mechanical hyperalgesia testing, rat 
PWT in response to stimulation of Von-Frey filaments (ranging from 0.0174 to 263 g, 
Autonomic Neuroscience Centre, London) to the lateral plantar surface of the tested 
paw until it withdrew [32]. Each monofilament was applied ten times. The PWT was 
taken as the force at which the animal withdrew the paw from at least five consecutive 
stimuli. The person conducting the behavioral measurements was blind to the 
treatments. 
 
Measuring of hind paws’ volumes 
According to the methods reported previously [32], the paw size of rats were assessed 
by using Drain-age Act [33].  
 
Visceromotor reflex (VMR) recording 
Rats were implanted with electromyogram (EMG) electrodes 5–7 days before testing. 
On the day of experiment, a balloon was lubricated and placed into the distal colon of 
the so that the tip of the balloon was 2 cm proximal to the anus. The intracolonic 
balloon was manually inflated using an air-filled syringe which allowed slow, 
continuous inflation. The visceromotor response was measured using 20, 40, 60, 
80mmHg CRD (four distensions at each pressure, 20 s each, 3 min interstimulus 
interval) [31, 34]. The intracolonic and balloon pressures and the EMG trace were 
continuously recorded after instrument calibration. The visceromotor response (the 
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EMG in response to CRD) was recorded with a CED 1401plus and analyzed using 
Spike 2 for Windows software (Cambridge Electronic Design, UK). The EMG was 
rectified offline and the area under the curve (AUC) determined. The baseline 
visceromotor response was defined as the AUC 10 s prior to distension. 
 
Western Blotting 
Rats were sacrificed and then lumbosacral DRG, spinal cord dorsal horn (SCDH) and 
rectocolon were obtained. Frozen rectocolonic tissues were weighed and 
homogenized in ice cold buffer (50 mM Tris-HCl, pH 7.5, 8 mM MgCl2, 5 mM 
ethylene glycol bis (2-aminoethyl ether)-N,N,N’N’-tetraacetic acid (EGTA), 0.5 mM 
EDTA, 0.01 mg/ml leupeptin, 0.01 mg/ml pepstatin,0.01 mg/ml aprotinin, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 250 mM NaCl). Homogenates were 
centrifuged (12,000× g, 15 min, 4 ºC) and the supernatants were collected and stored 
at -80 ºC. Protein concentration of the homogenate was determined following 
Bradford’s colorimetric method. Aliquots of supernatants containing equal amounts of 
protein (50μg) were separated on 10% acrylamide gel by sodium dodecyl sulfate 
polyacryamide gel electrophoresis. In the next step, the proteins were 
electrophoretically transferred onto a nitrocellulose membrane and incubated with 
specific primary antibodies: P2X3R (1:1000, Abcam, USA), c-fos (1:200, Santa Cruz, 
USA) and extracellular signal-regulated kinase (ERK) (1:200, Santa Cruz, USA). 
Each filter was washed three times for 15 min and incubated with the anti-rabbit 
immunoglobulin G antibodies for P2X3R, and for c-fos and ERK. To prove equal 
loading, the blots were analyzed for β-actin expression using an anti-β-actin antibody 
(1:8000, Sigma-Aldrich, MO, USA). Immunodetection was performed using 
enhanced chemiluminescence light-detecting kit (Santa Cruz, USA). Densitometric 
data were studied following normalization to the control (housekeeping gene). The 
signals were analyzed and quantified by a Scientific Imaging Systems (KODAK 1D, 
Image Analysis Software). 
 
Chemicals 
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CFA, TNBS, ERB-041 and U0126 were all purchased from Sigma-Aldrich, St. Louis, 
USA. DPN was purchased from Tocris. 17-estradiol was prepared in deionized water 
and stored frozen, while DPN, ERB-041 were dissolved in ethanol to 1 mM. U0126 
were dissolved in DMSO to 1 mM. 
 
Statistical analysis 
    Data are expressed as means ± SEM. Data in the behavior test were analyzed 
using two-way ANOVA. Unpaired Student’s t test analysis in SPSS11 was performed 
in c-fos expression between control and CFA groups. One-way ANOVA analysis was 
performed in the P2X3, c-fos and ERK expression among control, OVX and 
estrogen-treated OVX groups. Unpaired Students’ t test analysis in SPSS16 was 
performed in the experiments using Western Blotting techniques. Differences among 
the groups were considered statistically significant when the p value was lower than 
0.05 (p < 0.05).  
 
Results 
The ER agonist DPN reversed the decrease of PWT induced by CFA injection in 
normal female rats 
Compared with the control (saline + saline) group, plantar injection of CFA could 
significantly decrease the mechanical PWT (Fig.1A, n=8, p<0.01). ER agonists DPN 
and ERB-041 were peripherally applied to study the effect on the PWT of CFA rats. 
On the 3rd day after plantar injection of CFA, saline (500 l), DPN (3mg/kg, in 500 l 
saline) or ERB-041 (1mg/kg, in 500 l saline) were given on the following 4 
consecutive days. ER agonist DPN significantly reversed the PWT of CFA rats 
(Fig.1A,B, n=8, p<0.05) on the 8th day after CFA injection. Another ER agonist 
ERB-041 lacked the similar effect (Fig.1A,B, n=8, p>0.05).  
The volume of the left hind paws was significantly increased after plantar 
injection of CFA (Fig.1C, n=8, p<0.05). However, neither DPN nor ERB-041 reversed 
the increase induced by CFA (Fig. 1C, n=8, p>0.05; n=8, p>0.05).  
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ER agonists play a therapeutic role in TNBS-induced colitis rats 
Rats with colitis induced by TNBS soon developed severe abdominal pain, 
diarrhea and even bloody stools, which were characterized by a significant decrease in 
body weight and a significant increase in DAI scores. On the 4th day after colonic 
injection of TNBS, rats were given saline (500 l), the ER agonists DPN or 
ERB-041 (1mg/kg, in 500 l saline) on the following 4 consecutive days. The results 
showed that compared with those of the colitis group, the loss of body weight was 
significantly reversed after DPN or ERB-041 treatment (Fig.2A, n=6 for each group, 
p<0.05, p<0.05). DAI scores were also decreased markedly after DPN or ERB-041 
treatment (Fig.2B, n=6 for each group, p<0.05, p<0.05). 
We then tested the changes in VMR after application of DPN by using a colitis 
model induced by colonic injection of TNBS. Diagram showed the relationship 
between the magnitude of VMR and the colonic distension pressure in the colitis rats 
with or without DPN application. Compared with that in the colitis rats, the 
magnitude of the VMR in the DPN-treated rats was significantly decreased (Fig. 2C, 
n=6 for each group, p<0.05). 
 
Involvement of P2X3 receptors in TNBS-induced colitis rats 
    A317491, a selective antagonist of P2X3R, was used subcutaneously to treat 
colitis in the rats [28]. On the 3rd day after TNBS injection, rats were given saline 
(500 l), or A317491 (1mg/kg, in 500 l saline) on the following 4 consecutive days. 
The results showed that compared with that of the saline group, the loss of body 
weight was significantly reversed in the A317491 group (Fig.3A, n=6 for each group, 
p<0.05 compared with the saline group). DAI scores were also decreased markedly 
after A317491 administration (Fig.3B, n=6 for each group, p<0.05 compared with the 
saline group). 
We further investigated P2X3R expression in rectocolon, DRG and SCDH before 
and after TNBS administration. On the 4th day after TNBS injection, the expression of 
P2X3R in both rectocolon and DRG were significantly increased compared with those 
of the saline group (n=8 for each group, p<0.05).While in SCDH, there was no 
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marked change (Fig.3C, n=8 for each group, p<0.05 compared with the saline group).  
 
Effects of ER agonists DPN and ERB-041 on P2X3R expression in both CFA and 
colitis in rats 
DPN and ERB-041 are selective agonists for ER [16-17]. We investigated the 
effect of ER activation on P2X3R expression by using DPN and ERB-041. To 
further investigate the role of ERβ activation in the protein level after CFA 
administration, DRG and SCDH were isolated for western blotting on the 8th day after 
CFA injection. The results showed that the expression of P2X3R in DRG of CFA rats 
was significantly increased compared with that of the saline group, while in SCDH, 
there was no significant change (data not shown). After application of DPN, the 
expression of P2X3R in DRG was significantly decreased compared with that of 
saline-treated CFA rats (Fig.4A, n=8, p<0.05). While in SCDH, there was no 
significant change (Fig.4A, n=8, p>0.05). After application of ERB-041, there was no 
significant change in either DRG or SCDH (Fig.4B, n=8, p>0.05, p>0.05). 
We then investigated the possible effect of ER activation on P2X3R in colitis. 
Injection of DPN (10 g) for 4 days decreased P2X3R protein expression in colitis. 
The expression of P2X3R in rectocolon, DRG and SCDH of rats with colitis were all 
significantly decreased compared with those of the saline group (Fig.5A, n=6 for each 
group, p<0.05, p<0.05, p<0.05). However, after treatment with ERB-041, the 
expression of P2X3R was decreased significantly only in rectocolon but not DRG or 
SCDH, compared with those of the saline group (Fig.5B, n=6 for each group, p<0.05, 
p>0.05, p>0.05).  
 
Estrogen replacement reversed the decrease of PWT in ovariectomized CFA rats 
We then investigated the effect of estrogen on OVX CFA rats. Four weeks after 
replacement of estrogen or sesame oil in rats, there was a significant difference in 
mechanical pain threshold among all three groups (Fig. 6A, n=8 for each group, 
p<0.01). On the 1st day, mechanical PWT of the sham, OVX and estrogen-treated 
groups were decreased from (10.67±1.48)g, (8.16±1.60)g, (10.54±1.52)g to 
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(7.56±0.96)g, (6.29±1.99)g, (8.08±0.00) g after CFA injection, respectively, which 
were significantly different compared with that tested before CFA administration (Fig. 
6A,B, p<0.01, p<0.01, p<0.01). Subsequently, the PWT of the three groups declined, 
but not significantly (Fig. 6A, p>0.05, n=8 for each group). PWT of OVX (0.09±0.02 
g) was significantly lower than that of the sham group (1.08±1.04 g, p<0.05), which 
was then reversed by estrogen replacement (Fig. 6A, n=8 for each group, p<0.05). 
The difference sustained till day 11 after CFA injection (Fig. 6A). Before injection of 
CFA, the PWT in OVX rats was significantly decreased compared with that of sham 
rat (n=8 for each group p<0.01), which was then reversed by estrogen-treatment (n = 
8 for each group, p<0.01) (Fig. 6B). 
In order to observe the effect of CFA on the inflammatory progress of rats, 
Drainage Act was used to measure the volume of the left hind limb. On the 1st day 
after CFA injection, the volume of the left hind limbs in the sham, OVX and 
estrogen-treated groups rapidly increased from (1.44±0.09) ml, (1.39±0.19) ml, 
(1.38±0.13) ml to (1.89±0.23) ml, (2.06±0.15) ml, (1.98±0.16) ml. There were 
significant differences between pre-injection and injection in all three groups (Fig. 6C, 
p <0.01, p<0.01, p <0.01, n=8 for each group), indicating the successful induction of 
plantar inflammation. There was no significant difference in plantar volumes between 
sham and OVX rats (Fig. 6C, p >0.05). On day 5, 7, 9 and 11 after CFA injection, the 
plantar volume of estrogen-treated rats was significantly less than that of OVX rats 
(Fig. 6C, p<0.01, p<0.05, p<0.01, p<0.05). 
 
Estrogen replacement decreased the upregulation of P2X3R expressions in DRG from 
ovariectomized CFA rats 
 We then investigated the expression of P2X3R in sham, OVX and 
estrogen-treated CFA rats. In CFA rats, the total P2X3R protein obtained from DRG 
isolated from OVX rats was significantly increased compared with that from sham 
rats (Fig. 6D, n=6 for each group, p <0.05), which was then reversed by estrogen 
replacement (Fig. 6D, p <0.05).  
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Involvement of ERK and c-fos after estrogen replacement in ovariectomized CFA rats 
We then further investigated the expressions of ERK and c-fos in the sham, OVX 
and estrogen-treated CFA rats, The results showed that the expression of total ERK 
protein in lumbosacral DRG (Fig. 7A) and SCDH (Fig. 7B) of the estrogen-treated 
group was significantly lower than those of OVX rats (n=8 for each group, p<0.05, 
p<0.05). However, there was no significant difference in the expression of total ERK 
in DRG between OVX and Sham rats (Fig. 7A, p>0.05). The ERK expression was 
significantly increased after ovariectomy in SCDH compared with that of the sham 
rats (Fig. 7B, p<0.05). 
Western blot results also showed that the expression of c-fos protein in SCDH of 
the estrogen-treated group was significantly lower than that of OVX rats. (Fig. 7C, 
n=8 for each group, p<0.01). However, there was no significant change in the 
expression of c-fos protein of OVX group compared with that of the sham group (Fig. 
7C, p>0.05). We finally tested the PWT changes after plantar injection of U0126 in 
OVX rats. The results showed that the PWT was significantly increased 20 min after 
injection and maintained until 80 min (Fig. 7D, n=6 for each group, p<0.05, p<0.01, 
p<0.05, p<0.05), compared with those time points of control rats. 
 
Discussion 
In the present study, ERβ agonists, DPN or ERB-04, significantly decreased 
mechanical hypersensitivity in CFA-treated rats and inflammatory pain and responses 
in rats with colitis. The higher expressions of P2X3R in DRG of CFA-treated rats and 
those in rectocolon and DRG of TNBS-treated rats were all decreased by injection of 
DPN or ERB-041. Mechanical hyperalgesia and increased P2X3 expression in 
ovariectomized CFA-treated rats were then reversed by estrogen replacement. 
Furthermore, the expressions of ERK in DRG and SCDH and c-fos in SCDH were 
significantly decreased after estrogen replacement compared with those of OVX rats. 
The ERK antagonist U0126 significantly reversed mechanical hyperalgesia in the 
OVX rats. These results suggest that activation of ERβ may play an important 
therapeutic role in inflammation through down-regulation of P2X3R in peripheral 
 13 
 
tissues and the nervous system. 
 
 The modulation of estrogen via ERβ in inflammatory pain (perhaps better is: 
Estrogen modulates inflammatory pain via ERβ) 
Evidence has shown that estradiol replacement has an anti-nociceptive effect in 
OVX rats [24, 35-36]. Here we found that during inflammation, estrogen replacement 
significantly reversed hyperalgesia in the ovariectomized CFA-treated ratsl. ERβ is 
widely expressed on small-sized nociceptive DRG neurons and the colon, suggesting 
modulation in peripheral pain signal transduction [37, 38, 39]. Reports have shown 
that the selective ERβ agonist ERB-131 regulated nociception during the 
inflammatory state [18-19, 40]. In the present study, the ER agonist DPN inhibited 
mechanical pain sensitivity in CFA-treated rats and visceral pain in rats with colitis. 
These results indicate that ERβ activation might play a specific role in alleviating 
chronic nociception. Our previous study showed that application of estradiol in rat 
hind-paws rapidly inhibited ATP-induced peripheral hyperalgesia via ERα and GPR30 
[30, 32]. Therefore, we suggest that the anti-nociceptive effect of estrogen on OVX 
rats is probably via ERβ rather than ER.  
 
The modulation of estrogen on P2X3R via ERβ in inflammatory pain (perhaps better 
is: Estrogen modulates P2X3R via ERβ in inflammatory pain) 
It is well accepted that up-regulated expression and enhanced activity of P2X3R 
in DRG neurons is closely associated with the development and maintenance of acute 
and chronic pain [41-42]. Activation of P2X3R stimulates different cells, such as 
neurons or immunocytes, to cause abnormal excitability or release inflammatory 
mediators, including TNFα, IL-1β and leukotriene, to induce inflammation [24,26, 
43]. Our results show that the expression of P2X3R in neurons was significantly 
increased in CFA-treated rat [44] and in TNBS-induced colitis in rats [24, 26], 
indicating a vital role of P2X3R in inflammatory reactions. It has been reported that 
estrogen replacement decreased P2X3 upregulation in DRG after ovariectomy [31]. In 
the present study, estrogen replacement significantly decreased peripheral pain 
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sensitivity and P2X3R expression in DRG from CFA-treated OVX rats. The higher 
expressions of P2X3R in DRG of CFA-treated rats and those in rectocolon and DRG 
of TNBS-treated rats were all decreased by injection of ERβ agonists DPN or 
ERB-041. These results suggest that in chronic inflammatory pain, estrogen might 
inhibit P2X3R expression in primary sensory neurons through ERβ. Although the two 
agonists were both beneficial to colitis, some minor differences between DPN and 
ERB-041 in their modulatory function on P2X3R were found. After using DPN, the 
expression of P2X3R was decreased in rectocolon, DRG and SCDH, while a similar 
decrease was observed only in rectocolon after ERB-041 application. Based on the 
fact at DPN may easily passes through the blood-brain barrier to develop its role in 
the central nervous system, while ERB-041 can not [35,45], we suggest that action of 
ERB-041 might be limited to the rectocolon, while DPN might have roles in both the 
peripheral and central nervous systems. The underlying mechanisms of differences 
between DPN and ERB-041 need further study.  
 
Functions of ERK in the modulation of estrogen in inflammatory pain 
ERK is one member of the mitogen-activated protein kinase (MAPK) family, 
which is known to have different functions in sensory processing [46-48]. ERK 
functions as threonine/tyrosine double kinases and thus phosphorylates a series of 
transcription factors, including c-fos [49-50], and thus modulates protein synthesis 
[51]. Evidence has also shown that ERα and ERβ activate different signal transduction 
pathways, especially the MAPK system, which is usually determined by intracellular 
protein phosphorylation or calcium increase [52-53]. We found that after CFA 
application, expression of ERK in SCDH from OVX rats was significantly higher 
than that of controls, which was reversed by estrogen replacement. These results 
indicate that the inhibitory role of estrogen in pain perception might be related to the 
inhibition of ERK, probably with subsequent genetic transcription and protein 
synthesis. In DRG, the expression of ERK did not change after OVX compared with 
that of the sham group, but was significantly decreased in the estrogen-treated OVX 
group. The possible contribution of progesterone and other associated steroids from 
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intact gonads should probably also be taken into account.  
Reports have shown that phosphorylated ERK-positive neurons co-express 
P2X3R [54]. Injection of TNP-ATP, which antagonizes P2X3 and P2X2/3 receptors, 
into the inflamed joint reduced the phosphorylated ERK and the struggle behavior in 
CFA rats [55]. These results suggest the possible contribution of ERK in the 
hypersensitivity of P2X3R-induced inflammation. In the present study, although we 
could not demonstrate a direct relationship between ERK and P2X3R, the results 
support the views that estrogen replacement might inhibit the expression of P2X3R in 
DRG neurons through ERβ, as well as the expression of ERK, thus playing a 
regulatory role in inflammatory pain.  
 
Functions of c-fos in the modulation of estrogen in inflammatory pain 
Being an immediate early gene, c-fos can characterize neuronal excitation after 
certain stimulations and is an ideal location marker for central nervous activity 
[56-57]. Activation of ERK could transcriptionally activate c-fos, and lead to 
increased expression [58]. In this study, we found that in SCDH from estrogen-treated 
OVX rats, the expression of c-fos was significantly lower than that of OVX rats. 
Combined with the correlation between ERK and c-fos, the results in the present 
study indicate that, at least at the level of SCDH, the regulatory role of estrogen in 
pain might be through regulation of the expression of ERK, then that of c-fos, and 
subsequently the regulation of gene transcription. 
In conclusion, our results demonstrate that estradiol might inhibit CFA-induced 
chronic inflammatory pain through inhibiting the expression of P2X3R and ERK in 
the DRG, and the expression of c-fos and ERK in the spinal cord. Similarly, ER 
agonists improved TNBS-induced colitis, through down-regulating the expression of 
P2X3R. Our study further supports the view that the inhibitory effect of estrogen in 
inflammatory pain indicates that the effect of estrogen is probably via ERβ, and 
provides clues for clarifying the regulatory mechanism of estrogen in inflammatory 
pain perception. 
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Figure legends: 
Figure 1 
Changes in CFA-induced paw withdrawal threshold (PWT) and volumes of the left 
hind-paw among the three groups of female rats after injection of saline (100l) or 
CFA (100l) in the left hind-paw. (A) PWT of the group given CFA was significantly 
lower than that of the saline group (n=8). On the 8th day after CFA was applied, PWT 
of DPN-treated rats was significantly increased compared with that of saline-treated 
CFA rats (n=8). There was no significant difference between saline-treated CFA rats 
and ERB-041-treated CFA rats (n=8). * p<0.05 (B) On the 8th day after CFA or saline 
injection, PWT of saline-treated CFA rats was significantly lower than that of saline 
rats (n=8). After treatment of DPN in CFA rats, PWT was significantly reversed (n=8), 
while similar changes were not observed after treatment with ERB-041, compared 
with that of saline-treated CFA rats (n=8). * p<0.05, ** p<0.01 (C) The volumes of 
left hind-paw of the groups given CFA were significantly larger than that of 
saline-treated rats (n=8). However, there was no significant difference among 
saline-treated, DPN-treated and ERB-041-treated CFA rats (n=8). 
 
Figure 2 
Changes in body weight and DAI scores after application of DPN and ERB-041 in 
TNBS rats. (A) The body weight of DPN or ERB-041-treated colitis rats was 
significantly increased compared with that of saline-treated colitis rats (n=6), which 
continued for at least 3 days. (B) The DAI scores of DPN or ERB041-treated colitis 
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rats were significantly decreased compared with that of saline-treated colitis rats 
(n=6), which also continued for at least 3 days. (C) Diagram showing the relationship 
between the magnitude of visceromotor reflex (VMR) and the colonic distension 
pressure in the colitis rats with or without DPN application. Compared with that in the 
colitis rats, the magnitude of the VMR in DPN-treated rats was significantly 
decreased (n=6).* p<0.05 
 
Figure 3 
(A) Compared with that of the saline group, the loss of body weight was significantly 
reversed in the A317491-treated group (n=6). (B) Compared with that of the saline 
group, DAI scores were also decreased markedly after A317491 administration (n=6). 
*p<0.05 (C) Expression of P2X3R in rectocolon, DRG and SCDH in TNBS-induced 
colitis in rats. On the 4th day after TNBS injection, the expression of P2X3R in both 
rectocolon and DRG were significantly increased compared with those of the saline 
group (n=8).While in The SCDH, there was no marked change (n=8). * p<0.05 
compared with the saline group. 
 
Figure 4 
Expression of P2X3R protein in DRG and SCDH in saline-treated, DPN-treated and 
ERB-041-treated CFA rats. (A) Compared with that in the saline-treated CFA group, 
the expression of P2X3R was significantly decreased after DPN in DRG (n=8), while 
there was no significant change in SCDH (n=8). (B) Compared with that in the 
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saline-treated CFA group, the expression of P2X3R did not significantly change after 
ERB-041 was given in either DRG and SCDH (n=8). * p<0.05 
 
Figure 5 
Expression of P2X3R in rectocolon, DRG and SCDH in saline-treated, DPN-treated 
and ERB-041-treated rats with colitis induced by colonic injection of TNBS. (A) 
Compared with that in the saline-treated group, the expression of P2X3R was 
significantly decreased in the rectocolon, DRG and SCDH in the DPN-treated group 
(n=6). (B) Compared with that in the saline-treated group, in the ERB-041-treated 
group, the expression of P2X3R was significantly decreased only in the rectocolon 
(n=6), but not in DRG or SCDH (n=8). * p<0.05 
 
Figure 6 
Changes in left hind paw volume and the mechanical pain threshold (PWT) and 
expression of P2X3R after injection of CFA in the left hind-paw. (A) Two days after 
injection of CFA, PWT was significantly decreased compared with that of 
pre-injection (n=8), while there was no differences among groups (n=8). The decline 
of PWT reached a maximum on day 7 after CFA injection. The PWT of OVX rats was 
significantly lower than that of the sham group (n=8), which was then reversed by 
estrogen replacement (n=8). The difference was sustained until day 11 after CFA 
injection. * p<0.05, compared with the sham group. (B) Before injection of CFA, the 
PWT in OVX rats was significantly decreased compared with that of sham rats (n=8), 
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which was then reversed by estrogen treatment (n=8). * p<0.01 (C) On the 1st day 
after injection of CFA, the volume of the left hind paw was increased significantly 
compared with that of pre-injection (n=8). The volume of the left hind paw in 
estrogen-treated OVX rats was significantly decreased compared with that of OVX 
rats (n=8). There was no significant difference in plantar volumes between sham and 
OVX rats. On days 5, 7, 9 and 11 after CFA injection, the plantar volume of 
estrogen-treated rats was significantly less than that of OVX rats. * p<0.05, ** p<0.01, 
compared with the OVX group. (D) In CFA rats, the total P2X3R protein obtained 
from DRG isolated from OVX rats was significantly increased compared with that 
from sham rats (n=6), which was then reversed by estrogen replacement for 4 weeks. 
* p<0.05 
 
Figure 7 
Expressions of ERK and c-fos proteins in DRG and SCDH from sham, OVX and 
estrogen-treated OVX rats. (A) The total expression of ERK in DRG, expressed as 
blot density relative to OVX rats, was decreased significantly in estrogen-treated rats 
(n=8). There was no significant difference between the OVX and sham group (n=8). 
(B) The total expression of ERK in SCDH, expressed as blot density relative to sham 
rats, was increased significantly in OVX group (n=8) and then reversed in the 
estrogen-treated group (n=8). (C) Relative to OVX rats, the expression of c-fos was 
decreased significantly in estrogen-treated rats (n=8). There was no significant 
difference between the OVX and sham groups (n=8). *p<0.05, **p<0.01 (D) PWT 
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changes following plantar injection of U0126 in OVX rats. PWT was significantly 
increased 20 min after injection and was maintained until 80 min (n=6), compared 
with control rats. * p<0.05, ** p<0.01 
 
